9-(β-(DL)-erythro-furanosyl)guanine | 106445-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(β-(DL)-erythro-furanosyl)guanine
• 英文别名: 9-[β-(DL)-erythro-furanosyl]guanine；Erythrofuranosylguanosine；2-amino-9-[(2R,3R,4R)-3,4-dihydroxyoxolan-2-yl]-1H-purin-6-one
• CAS: 106445-21-0；138874-51-8
• 化学式: C₉H₁₁N₅O₄
• 分子量: 253.217
• InChiKey: QCVOCLNEIVZAML-TWOGKDBTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  135
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-2-乙酰鸟嘌呤 在 三氟甲磺酸三甲基硅酯 、 氨 、 六甲基二硅氮烷 作用下， 以 甲醇 为溶剂， 反应 59.0h， 生成 9-(β-(DL)-erythro-furanosyl)guanine
  参考文献：
  名称：

  (13C)-Substituted erythronucleosides: synthesis and conformational analysis by proton and carbon-13 NMR spectroscopy

  摘要：

  The erythronucleosides, 9-beta-D-erythrofuranosyladenine (1b), 1-beta-D-erythrofuranosylcytosine (2b), 9-beta-D-erythrofuranosylguanine (3b), and 1-beta-D-erythrofuranosyluracil (4b), were synthesized with and without C-13-substitution at C1' of the furanose ring. 75-MHz C-13 and 620-MHz H-1 NMR spectra of 1-4b were interpreted, in the latter case with the assistance of spectral simulation, and H-1-H-1, C-13-H-1, and C-13-C-13 spin couplings were used to assess furanose conformation. 3J(HH) data in (H2O)-H-2 were treated by computer to determine the preferred north and south conformers, their puckering amplitudes, and their mole fractions in solution, and J(CH) data were used to complement this analysis. A similar treatment of spin coupling data for the corresponding ribonucleosides 1-4a was also conducted to permit a comparison of furanose conformations in both series of compounds. Results show that the removal of the exocyclic hydroxymethyl group from 1-4a, giving 1-4b, significantly enhances the proportion of south conformers in aqueous ((H2O)-H-2) solution.

  DOI：

  10.1021/jo00032a032

文献信息

• Compounds and pharmaceutical compositions for the treatment of viral infections
  申请人：IDENIX Pharmaceuticals, Inc.

  公开号：EP2476690A1

  公开（公告）日：2012-07-18

  Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝脏疾病（包括 HCV 感染）的化合物、组合物和方法。具体来说，本文公开了核苷衍生物的化合物和组合物，可单独使用或与其他抗病毒药物联合使用。
• McGee, Danny P. C.; Martin, John C., Canadian Journal of Chemistry, 1986, vol. 64, p. 1885 - 1889
  作者：McGee, Danny P. C.、Martin, John C.

  DOI：——

  日期：——
• KLINE, PAUL C.;WU, JIAN;SERIANNI, ANTHONY S., 197TH ACS NAT. MEET., DALLAS, TEX., APR. 9-14, 1989, WASHINGTON (D. C.),(+
  作者：KLINE, PAUL C.、WU, JIAN、SERIANNI, ANTHONY S.

  DOI：——

  日期：——
• GLYCOPEGYLATED ERYTHROPOIETIN
  申请人：DeFrees Shawn

  公开号：US20120107867A1

  公开（公告）日：2012-05-03

  The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
• ASSOCIATION OF A TETRAPEPTIDE AND A GLYCERYL ESTER FOR TREATING ANDROGENIC ALOPECIA
  申请人：PIERRE FABRE DERMO-COSMETIQUE

  公开号：US20170080046A1

  公开（公告）日：2017-03-23

  The invention relates to an association comprising a peptide containing the sequence A-Lys-Gly-His-Lys-NH 2 , wherein A is the radical corresponding to a C 1 to C 18 saturated or unsaturated fatty acid, and glyceryl laurate or one of the derivatives thereof. The invention also relates to the use thereof for stimulating hair growth.